sprite-preloader
Anzeige
Mehr »
Freitag, 22.09.2017 Börsentäglich über 12.000 News von 560 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A1W5NZ ISIN: US3504651007 Ticker-Symbol: 8FM 
Aktie:
Branche
Biotechnologie
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
FOUNDATION MEDICINE INC Chart 1 Jahr
1-Woche-Intraday-Chart
FOUNDATION MEDICINE INC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
32,005
32,891
09:53
15.09.2017 | 17:33
(3 Leser)
Schrift ändern:
(0 Bewertungen)

ACCESSWIRE·Mehr Nachrichten von ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / September 15, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Foundation Medicine, Inc. ("Foundation") (NASDAQ: FMI) securities between February 26, 2014 and November 3, 2015.

Click here to learn about the case: http://www.wongesq.com/pslra-sbm/foundation-medicine-inc?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose material information regarding: (1) the reimbursement process and likelihood of coverage for Foundation's tumor tests by Medicare; and (2) the Company's financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.

On July 29, 2015, the Company disclosed that it was not making the strides obtaining coverage it had claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company slashed its 2015 financial guidance, which, unbeknownst to investors, was based on an assumption that Medicare approval was going to be obtained in 2015. Then, on November 3, 2015, the Company disclosed a further revision to the already reduced number of clinical tests it expected to report for 2015. Following this disclosure, the price of Foundation common stock fell to a close of $17.31 per share on November 4, 2015.

If you suffered a loss in Foundation, you have until September 26, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/foundation-medicine-inc?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong


© 2017 ACCESSWIRE